Risk evaluation of denosumab and zoledronic acid for medication-related osteonecrosis of the jaw in patients with bone metastases: a propensity score–matched analysis
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1433-7339
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Risk evaluation of denosumab and zoledronic acid for medication-related osteonecrosis of the jaw in patients with bone metastases: a propensity score–matched analysis ; day:5 ; month:11 ; year:2021 ; pages:1-8
Supportive care in cancer ; (5.11.2021), 1-8
- Creator
-
Ikesue, Hiroaki
Doi, Kohei
Morimoto, Mayu
Hirabatake, Masaki
Muroi, Nobuyuki
Yamamoto, Shinsuke
Takenobu, Toshihiko
Hashida, Tohru
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1007/s00520-021-06634-7
- URN
-
urn:nbn:de:101:1-2022011918065156633294
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:33 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Ikesue, Hiroaki
- Doi, Kohei
- Morimoto, Mayu
- Hirabatake, Masaki
- Muroi, Nobuyuki
- Yamamoto, Shinsuke
- Takenobu, Toshihiko
- Hashida, Tohru
- SpringerLink (Online service)
Other Objects (12)
Medication-related osteonecrosis of the jaw : bisphosphonates, denosumab, and new agents
Associated characteristics and treatment outcomes of medication-related osteonecrosis of the jaw in patients receiving denosumab or zoledronic acid for bone metastases
Switching from zoledronic acid to denosumab increases the risk for developing medication-related osteonecrosis of the jaw in patients with bone metastases
Risk factors associated with onset of medication-related osteonecrosis of the jaw in patients treated with denosumab
Risk factors associated with onset of medication-related osteonecrosis of the jaw in patients treated with denosumab
How we manage medication-related osteonecrosis of the jaw
Uncommon presentation of potential medication-related osteonecrosis of the jaw
Dental students' knowledge of medication-related osteonecrosis of the jaw
Pharmacoepidemiology and clinical characteristics of medication-related osteonecrosis of the jaw
Pathogenesis and multidisciplinary management of medication-related osteonecrosis of the jaw
Medication-related osteonecrosis of the jaw using periodontitis-induced rat before tooth extraction
Clinical considerations for medication-related osteonecrosis of the jaw: a comprehensive literature review
Medication-related osteonecrosis of the jaw : bisphosphonates, denosumab, and new agents
Associated characteristics and treatment outcomes of medication-related osteonecrosis of the jaw in patients receiving denosumab or zoledronic acid for bone metastases
Switching from zoledronic acid to denosumab increases the risk for developing medication-related osteonecrosis of the jaw in patients with bone metastases
Risk factors associated with onset of medication-related osteonecrosis of the jaw in patients treated with denosumab
Risk factors associated with onset of medication-related osteonecrosis of the jaw in patients treated with denosumab
How we manage medication-related osteonecrosis of the jaw
Uncommon presentation of potential medication-related osteonecrosis of the jaw
Dental students' knowledge of medication-related osteonecrosis of the jaw
Pharmacoepidemiology and clinical characteristics of medication-related osteonecrosis of the jaw
Pathogenesis and multidisciplinary management of medication-related osteonecrosis of the jaw
Medication-related osteonecrosis of the jaw using periodontitis-induced rat before tooth extraction
Clinical considerations for medication-related osteonecrosis of the jaw: a comprehensive literature review
Medication-related osteonecrosis of the jaw : bisphosphonates, denosumab, and new agents
Associated characteristics and treatment outcomes of medication-related osteonecrosis of the jaw in patients receiving denosumab or zoledronic acid for bone metastases
Switching from zoledronic acid to denosumab increases the risk for developing medication-related osteonecrosis of the jaw in patients with bone metastases
Risk factors associated with onset of medication-related osteonecrosis of the jaw in patients treated with denosumab
Risk factors associated with onset of medication-related osteonecrosis of the jaw in patients treated with denosumab
How we manage medication-related osteonecrosis of the jaw
Uncommon presentation of potential medication-related osteonecrosis of the jaw
Dental students' knowledge of medication-related osteonecrosis of the jaw
Pharmacoepidemiology and clinical characteristics of medication-related osteonecrosis of the jaw
Pathogenesis and multidisciplinary management of medication-related osteonecrosis of the jaw
Medication-related osteonecrosis of the jaw using periodontitis-induced rat before tooth extraction